医学影像在肾癌诊疗中的作用及思考

王林辉; 董凯; 吴震杰

doi:10.13201/j.issn.1001-1420.2022.09.001

医学影像在肾癌诊疗中的作用及思考

- 海军军医大学第一附属医院(上海长海医院)泌尿外科(上海，200433)

详细信息

作者简介:
王林辉，主任医师，教授，博士生导师。现任海军军医大学第一附属医院(上海长海医院)泌尿外科主任、全军计划生育优生优育技术研究所所长，上海市医师协会泌尿外科医师分会会长，上海市医学会男科学专科委员会主任委员，中华医学会泌尿外科分会委员，中国医师协会内镜医师分会副会长，中国医师协会男科与性医学会医师分会副会长，中国医师协会泌尿外科医师分会常委会委员，中国医师协会医学机器人医师分会常委会委员，上海市医学会第36届理事会理事，中国医师协会第4届理事会理事。担任《中国外科年鉴》副主编、《中华泌尿外科杂志》常务编委、《机器人外科学杂志》常务编委、《中国肿瘤生物治疗杂志》《中华腔镜外科杂志》《临床泌尿外科杂志》《微创泌尿外科杂志》等杂志编委。擅长泌尿系肿瘤的微创治疗、晚期肿瘤的综合治疗及前列腺增生、泌尿系统先天性疾病、损伤、结石的综合诊治。以通讯作者或第一作者发表论文180余篇，SCI论文60余篇，单篇影响因子最高27.4分，主编或副主编专著7部。作为项目主要负责人，先后主持国家自然科学基金重点项目、科技部重大专项课题、国家自然科学基金面上项目、军队重点研发项目等省部级以上基金20余项。先后获国家科技进步奖二等奖3项、教育部高等学校科学研究优秀成果奖(科技进步奖)一等奖1项、上海市科技进步奖一等奖2项、上海市科技进步奖二等奖2项、上海医学科技奖一等奖2项、军队医疗成果一等奖2项、军队医疗成果三等奖1项和军队科技进步三等奖1项。曾入选解放军总后勤部“科技新星”，上海市领军人才、上海市优秀学科带头人、上海市卫生系统“新百人“等人才计划项目；曾荣获上海市卫生系统银蛇奖一等奖、上海市仁心医者——杰出专科医师奖、第15届上海市科技精英、军队医疗工作先进个人等奖项荣誉。荣立军队个人二等功1次，军队个人三等功3次，2016年享受国务院特殊津贴。已培养硕士生26人，博士生27人

通讯作者: 王林辉，E-mail：wanglinhui@smmu.edu.cn

中图分类号: R737.11

收稿日期: 2022-07-30

刊出日期: 2022-09-06

Role and consideration of medical imaging in the diagnosis and treatment of renal cell carcinoma

- Department of Urology, Changhai Hospital, First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China

More Information

Corresponding author: WANG Linhui, E-mail: wanglinhui@smmu.edu.cn

Received Date: 30 July 2022

Publish Date: 06 September 2022

摘要

摘要: 随着影像学技术的发展和多学科治疗(multi-disciplinary treatment，MDT)模式的推进，肾癌的个体化治疗对影像学精准评估的要求日益增高。传统单纯的影像学定位和定性评判已无法满足现阶段肾癌外科综合治疗的需求，因此需要将影像学的应用场景在肾癌诊疗领域持续拓展。本文总结了医学影像在肾癌诊疗中的应用和研究进展，着重强调了泌尿外科医生最关注的临床痛点和瓶颈问题。从术前临床分期、术中引导治疗、术后随访到肾功能评价等方面，影像学已深度融入到肾癌诊断-治疗-随访的多环节、全过程，发挥指导临床诊疗的作用，但后续仍需突破机器分辨率低、模态单一、主观性干扰等局限，提供全方位、有价值的信息，使患者获益最大化。
- 肾癌 /
- 医学影像 /
- 诊断与治疗
Abstract: With the development of imaging techniques and the advancement of multi-disciplinary treatment, there is an increasing demand for accurate imaging evaluation in the individualized treatment of renal cell carcinoma. The conventional imaging localization and qualitative diagnosis have been unable to meet the current needs of comprehensive surgical treatment of renal cell carcinoma, so it is necessary to expand the application scene of imaging in the diagnosis and treatment of renal cell carcinoma. This paper summarizes the application and research progress of medical imaging in the diagnosis and treatment of renal cell carcinoma, and emphasizes the difficulties and bottlenecks that are the most concerns among urologists. In terms of preoperative clinical staging, intraoperative guidance, postoperative follow-up, and the evaluation of renal function, imaging has been deeply integrated into the whole process of diagnosis, treatment and follow-up of renal cell carcinoma, and plays an important role in guiding clinical diagnosis and treatment. However, the limitations of low resolution, single mode and subjective interference remain to be resolved to provide omni-directional and valuable information to maximize the benefits of patients.
- renal cell carcinoma /
- medical imaging /
- diagnosis and treatment

HTML全文

图 1 肾癌影像学形态分类

下载: 全尺寸图片幻灯片

图 2 提示肿瘤侵犯肾周脂肪或肾窦脂肪的影像学特征

下载: 全尺寸图片幻灯片

图 3 荧光引导肾动脉分支阻断后肾部分切除术示意图

下载: 全尺寸图片幻灯片

参考文献(30)

[1]	Türkvatan A, Akdur PO, Altinel M, et al. Preoperative staging of renal cell carcinoma with multidetector CT[J]. Diagn Interv Radiol, 2009, 15(1): 22-30.
[2]	Sheth S, Scatarige JC, Horton KM, et al. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT[J]. Radiographics, 2001, 21 Spec No: S237-S254.
[3]	Hamilton ZA, Capitanio U, Pruthi D, et al. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T_1-2 Renal Cell Carcinoma Patients Upstaged to pT_3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria[J]. Urology, 2020, 138: 60-68. doi: 10.1016/j.urology.2019.11.036
[4]	Krishna S, Schieda N, Flood TA, et al. Magnetic resonance imaging(MRI)of the renal sinus[J]. Abdom Radiol(NY), 2018, 43(11): 3082-3100. doi: 10.1007/s00261-018-1593-1
[5]	Liu BX, Sun W, Kong XQ. Perirenal Fat: A Unique Fat Pad and Potential Target for Cardiovascular Disease[J]. Angiology, 2019, 70(7): 584-593. doi: 10.1177/0003319718799967
[6]	Margulis V, Wood CG. Update on staging controversies for locally advanced renal cell carcinoma[J]. Expert Rev Anticancer Ther, 2007, 7(7): 909-914. doi: 10.1586/14737140.7.7.909
[7]	Teishima J, Hayashi T, Kitano H, et al. Impact of radiological morphology of clinical T₁ renal cell carcinoma on the prediction of upstaging to pathological T₃[J]. Jpn J Clin Oncol, 2020, 50(4): 473-478. doi: 10.1093/jjco/hyz154
[8]	Damgaci L, Ozer H, Rona G. Diagnostic value of MDCT in determining the perinephric fat tissue and renal sinus invasion in patients with clear cell renal cell carcinoma[J]. Niger J Clin Pract, 2021, 24(4): 489-495.
[9]	Lal H, Singh P, Jain M, et al. Role of MRI in staging and surgical planning and its clinicopathological correlation in patients with renal cell carcinoma[J]. Indian J Radiol Imaging, 2019, 29(3): 277-283. doi: 10.4103/ijri.IJRI_177_19
[10]	Thompson RH, Leibovich BC, Cheville JC, et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT_3a renal cell carcinoma?[J]. J Urol, 2005, 174(4 Pt 1): 1218-1221.
[11]	Gill IS, Cacciamani GE, Duddalwar V, et al. Renal cancer with extensive level IV intracardiac tumour thrombus removed by robot[J]. Lancet, 2020, 396(10262): e88. doi: 10.1016/S0140-6736(20)32291-1
[12]	Reese AC, Whitson JM, Meng MV. Natural history of untreated renal cell carcinoma with venous tumor thrombus[J]. Urol Oncol, 2013, 31(7): 1305-1309. doi: 10.1016/j.urolonc.2011.12.006
[13]	Blute ML, Leibovich BC, Lohse CM, et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus[J]. BJU Int, 2004, 94(1): 33-41. doi: 10.1111/j.1464-410X.2004.04897.x
[14]	Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T_3b the same?[J]. J Urol, 2004, 171(2 Pt 1): 598-601.
[15]	冯翔, 吕晨, 陈锐, 等. 下腔静脉延迟阻断法在Mayo 2级静脉癌栓取出术中的应用(附光盘)[J]. 现代泌尿外科杂志, 2019, 24(5): 332-335. doi: 10.3969/j.issn.1009-8291.2019.05.002
[16]	Liu Z, Li L, Hong P, et al. A Predictive Model for Tumor Invasion of the Inferior Vena Cava Wall Using Multimodal Imaging in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus[J]. Biomed Res Int, 2020, 2020: 9530618.
[17]	时佳子, 叶华茂, 徐志鹏, 等. 专用超声在机器人辅助腹腔镜肾部分切除术中的应用初探[J]. 临床泌尿外科杂志, 2016, 31(1): 29-30, 34. http://www.cnki.com.cn/Article/CJFDTotal-LCMW201601010.htm
[18]	Gill IS, Patil MB, Abreu AL, et al. Zero ischemia anatomical partial nephrectomy: a novel approach[J]. J Urol, 2012, 187(3): 807-814. doi: 10.1016/j.juro.2011.10.146
[19]	范小明, 王力, 张大宏, 等. 腹腔镜超声在中央型肾肿瘤腹腔镜切除术中的应用价值[J]. 中华超声影像学杂志, 2011, 20(9): 772-774. doi: 10.3760/cma.j.issn.1004-4477.2011.09.014
[20]	Bates AS, Patel VR. Applications of indocyanine green in robotic urology[J]. J Robot Surg, 2016, 10(4): 357-359. doi: 10.1007/s11701-016-0641-5
[21]	刘承宗, 时佳子, 吴震杰, 等. 术中荧光在机器人辅助腹腔镜下肾部分切除术中的应用初探[J]. 临床泌尿外科杂志, 2018, 33(6): 446-449. http://www.cnki.com.cn/Article/CJFDTotal-LCMW201806007.htm
[22]	吴震杰, 王坚超, 刘承宗, 等. 区域血流荧光可视化成像在机器人肾部分切除术中的初步应用体会[J]. 中华泌尿外科杂志, 2017, 38(7): 489-492. doi: 10.3760/cma.j.issn.1000-6702.2017.07.003
[23]	吴震杰, 刘冰, 时佳子, 等. 荧光引导肾动脉分支阻断的机器人腹腔镜肾部分切除术("大家泌尿网"观看手术视频)[J]. 现代泌尿外科杂志, 2021, 26(9): 723-725. doi: 10.3969/j.issn.1009-8291.2021.09.002
[24]	Bruno JJ 2nd, Snyder ME, Motzer RJ, et al. Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival[J]. BJU Int, 2006, 97(5): 933-938. doi: 10.1111/j.1464-410X.2006.06076.x
[25]	Wu Q, Huang G, Wei W, et al. Molecular Imaging of Renal Cell Carcinoma in Precision Medicine[J]. Mol Pharm, 2022.
[26]	Muselaers CH, Stillebroer AB, Desar IM, et al. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma[J]. J Nucl Med, 2014, 55(2): 242-247. doi: 10.2967/jnumed.113.131110
[27]	Mittlmeier LM, Unterrainer M, Rodler S, et al. 18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results[J]. Eur J Nucl Med Mol Imaging, 2021, 48(6): 2031-2037. doi: 10.1007/s00259-020-05165-3
[28]	Oosting SF, Brouwers AH, van Es SC, et al. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment[J]. J Nucl Med, 2015, 56(1): 63-69. doi: 10.2967/jnumed.114.144840
[29]	Kayani I, Avril N, Bomanji J, et al. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer[J]. Clin Cancer Res, 2011, 17(18): 6021-6028. doi: 10.1158/1078-0432.CCR-10-3309
[30]	Liu G, Jeraj R, Vanderhoek M, et al. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate[J]. Clin Cancer Res, 2011, 17(24): 7634-7644. doi: 10.1158/1078-0432.CCR-11-1677